A new report from Invest Stockholm conducts a review of knowledge about neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Both the region’s academic research and selected companies are presented here.
The report highlights one of Flemingsberg’s knowledge companies: AlzeCure. Here, the company’s CEO Martin Jönsson talks about the development of new treatments for Alzheimer’s disease.
It is estimated that the number of people with dementia will increase from 50 million today to 150 million in 2050. Alzheimer’s disease is the most common form of dementia and is a major cause of disability and dependency among old people worldwide. Parkinson’s disease is the second most common age-related neurodegenerative disorder and can also have a devastating impact on quality of life.
Universities and research institutes in the greater Stockholm region are carrying out vital research into these diseases, which will help to achieve early diagnosis and reduce the impact of neurodegenerative conditions on people’s lives.
Read the new report from Invest Stockholm: Improving Quality of Life for People with Neurodegenerative Diseases
Photo: Anna Hugosson, mediabank.visitstockholm.com